Jens Hillengaß

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas

Efstathios Kastritis, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Wee Joo Chng et autres

Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence …

gr, us, sg, de, br, is, fr, es, ca, gb, kr, it (code pays fourni par la source)

Clinical and Metabolic Outcomes of Radiofrequency Ablation with Vertebral Augmentation for Symptomatic Spinal Osteolytic Lesions in Multiple Myeloma

Pooya Torkian, Jens Hillengaß, Younes Jahangiri, Farzin Takyar et autres

us (code pays fourni par la source)

More than an emotional support PET

Jens Hillengaß

us (code pays fourni par la source)

Analysis of epidemiologic factors and treatment effects on immunophenotypes in hematologic malignancy patients

Theresa Hahn, Megan M. Herr, Paul K. Wallace, Yali Zhang et autres

To the EditorImmunotherapy is common for hematologic diseases and personalizing treatment based on each patient’s immune status is of growing interest. Impaired or dysregulated immune cells have be...

us (code pays fourni par la source)

Treatment response assessment using whole body diffusion weighted-magnetic resonance imaging in myeloma: a retrospective cohort study

Rajshekhar Chakraborty, Khalid Shalaby, Sarah Parker, Sonali Lala et autres

This bi-institutional retrospective cohort study evaluated whole-body diffusion-weighted MRI (WB DW-MRI) for myeloma response assessment and its concordance with bone marrow minimal residual disease (MRD) testing. Among 53 patients, 49.1% achieved imaging complete response (imaging-CR; defined as no active focal lesions or …

us (code pays fourni par la source)

Circulating immune profile in patients with amyloidosis

Janine M. Joseph, Joseph Dennis Tario, Han Yu, Philip L. McCarthy et autres

Abstract Introduction Although both light-chain (AL) and transthyretin (ATTR) amyloidosis involve accumulation of misfolded proteins in one or more organs, these conditions have different origins. Whereas AL is an immune disorder caused by abnormal plasma cells in the bone marrow releasing amyloidogenic …

us (code pays fourni par la source)

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes et autres

ABSTRACT: Understanding the roles of myeloid cells in the tumor microenvironment (TME) has emerged as a promising strategy to identify novel targets to counteract the immunosuppressive barriers protecting multiple myeloma (MM). Neutrophils are a new cancer research focus due to their potential …

us, fr, jp (code pays fourni par la source)

Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur, Jill Corre et autres

The article by Avet-Loiseau et al entitled "International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of HighRisk Multiple Myeloma"(Journal of Clinical Oncology 10.1200/JCO-24-01893) was published online June 9, 2025, with errors. The author S. Bruno Paiva s name is …

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Hervé Avet‐Loiseau, Faith E. Davies, Mehmet Samur, Jill Corre et autres

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in …

fr, us, it, gb, de, es, ca, sg, au, nl (code pays fourni par la source)

NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025

Shaji Kunnathu Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson Jr. et autres

The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with MM. These NCCN Guidelines Insights highlight the important updates and changes specific to systemic therapy for patients with newly diagnosed as …

us, Afrique du Sud, in (code pays fourni par la source)

Spot Urine Protein/Creatinine Ratio as an Alternative to 24-Hour Urine Collection for Measuring Proteinuria in Patients With Multiple Myeloma: A Prospective Study

Saad Jamshed, Mohammad Ammad-Ud-Din, Kimberly Celotto, Jonathan Bress et autres

us (code pays fourni par la source)

Imaging in multiple myeloma

Jas Virk, Jens Hillengaß

us (code pays fourni par la source)